Prognostic Significance of Sarcomatous Change in Patients with Hepatocellular Carcinoma After Surgical Resection

Lu, Jiong; Xiong, Xian‐Ze; Li, Fuyu; Hui, Yi; Lin, Yixin; Zhou, Rongxing; Cai, Yulong; Jin, Yu; Cheng, Nan‐Sheng

doi:10.1245/s10434-015-4818-3

Cited by 21 publications

(32 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of sarcomatoid hepatocellular carcinoma (SHC) is quite low with ~2% in surgically resected cases and ~10% in autopsied cases 5, 6 . Although SHC is a very rare histologic variant of hepatocellular carcinoma (HCC), the prognosis of patients with the SHC was significantly worse than ordinary HCC cases 5, 7 . The poor prognosis has been attributed to the highly metastatic property of sarcomatous cells 8, 9 .…”

Section: Introductionmentioning

confidence: 99%

Characterization of a new murine cell line of sarcomatoid hepatocellular carcinoma and its application for biomarker/therapy development

Yen

Lai

Liao³

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Sarcomatoid hepatocellular carcinoma (SHC) is a rare type of HCC with significantly poorer survival than ordinary HCC. Little is known about the mechanism associated with SHC and its biomarkers and therapy. Here, we established a mouse liver cancer cell line and designated as Ymac-1. A sarcomatous appearance was observed in the allograft tumor arose from Ymac-1. Liver-secreted plasma proteins were found in Ymac-1 cultured supernatant by proteomics analysis. The positive staining of CK7, CK8, Vimentin and the suppressed expression of AFP indicated that Ymac-1 is a SHC cell line. Compared to its original tumor, an elevated level of EMT markers, N-cadherin and Vimentin, was found in Ymac-1. Ymac-1 displayed a higher migration rate and side population percentage than a mouse ordinary HCC cell line-Hepa1-6. Microarray analysis was performed to identify potential biomarkers/therapeutic targets for SHC. G6pd, a vital enzyme in pentose phosphate pathway, is highly expressed in Ymac-1. Depletion of G6pd in Ymac-1 reduced CD133 expression and sphere formation. Positive correlations between G6PD and CD133 were observed in human specimen. Higher expression of both G6PD and CD133 in tumor were associated with poor survival. In summary Ymac-1 can be a useful SHC cell model for novel biomarker and therapy development.

show abstract

Section: Introductionmentioning

confidence: 99%

Characterization of a new murine cell line of sarcomatoid hepatocellular carcinoma and its application for biomarker/therapy development

Yen

Lai

Liao³

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Previous investigators compared OS between patients with HCC with SC and ordinary HCC, whereas others analyzed the differences between ICC with SC and ordinary ICC. [8][9][10] In those studies, OS of patients with PLC-SC was significantly poorer than that of patients with ordinary HCC and ICC. [8][9][10] In our study, PLC-SC that included a large area of SC and large tumor size showed poorer prognosis than other PLC-SC.…”

Section: Discussionmentioning

confidence: 90%

“…[8][9][10] In those studies, OS of patients with PLC-SC was significantly poorer than that of patients with ordinary HCC and ICC. [8][9][10] In our study, PLC-SC that included a large area of SC and large tumor size showed poorer prognosis than other PLC-SC. Several previous studies suggested that the only way of improving prognosis in PLC-SC is early detection and complete resection of the tumor.…”

Section: Discussionmentioning

confidence: 90%

“…Although our study included only a small number of cases, it is the first to compare the prognosis of PLC‐SC based on the proportion of sarcomatous component and tumor size. Previous investigators compared OS between patients with HCC with SC and ordinary HCC, whereas others analyzed the differences between ICC with SC and ordinary ICC . In those studies, OS of patients with PLC‐SC was significantly poorer than that of patients with ordinary HCC and ICC .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases

Ohya

Saitoh

Fujiyama

et al. 2019

Hepatology Research

View full text Add to dashboard Cite

Primary liver carcinoma with sarcomatous change is a rare malignancy associated with high aggressiveness and poor prognosis. However, the characteristics of these types of tumors are still unknown. The aim of this study was to assess the imaging features, prognostic significance, and clinicopathological characteristics of patients with these tumors. Of 1070 patients who underwent surgical resection of primary liver carcinoma at Toranomon Hospital (Tokyo, Japan) from 2003 to 2017, 10 patients were diagnosed with primary liver carcinoma containing sarcomatous component. This study included all 10 patients. We evaluated the percentage of the sarcomatous component in each tumor. Patients were classified into two groups: the low percentage group (area of sarcomatous changes ≤30%) and high percentage group (area sarcomatous component ≥70%). We also divided patients into two groups based on the combination of the percentage of sarcomatous tissue and tumor size (≥40 mm or <40 mm). The overall survival rate of patients with ≥70% sarcomatous component and ≥40 mm tumor was significantly worse than that of patients with ≤30% sarcomatous tissue or <40 mm tumor size (P = 0.0059). The results confirmed the poor prognosis of patients with sarcomatous changes in primary liver carcinoma, especially those with large sarcomatous component and large tumor size. Radical resection in the early stage is recommended to improve prognosis.

show abstract

“…In the group of PHSs, recent studies have suggested that a combination of surgery and pre-or post-surgical chemotherapy can substantially improve clinical outcomes of the UES. For unresectable tumors, systemic chemotherapy and local radiotherapy can be options [7]. In the case of PHSCs, surgery would be justi ed as the primary treatment.…”

Section: Introductionmentioning

confidence: 99%

Clinical and imaging characteristics of primary hepatic sarcomatoid carcinoma and sarcoma: a comparative study

Shi

Sun

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background：Primary hepatic sarcomatous carcinoma (PHSC) and primary hepatic sarcoma (PHS) are rare malignancies with frequent overlap in both the clinic and radiology. No comparative study of these tumors for the restricted cases has previously been undertaken. The purpose of our study was to analyze the clinical and imaging features of PHSCs and PHSs, with an emphasis on particularities and similarities through a comparison of the two tumors.Methods: We retrospectively analyzed the clinical and imaging features of 39 patients with pathologically proven PHSCs (n=23) and PHSs (n=16) from four university centers over a 9-year period from 2010-2019. Univariate analyses were performed to determine the consistent and distinctive features. Results：The background of chronic hepatitis or cirrhosis was observed with a high frequency in both of PHSCs (73.7%) and PHSs (62.5%). Tumors with a diameter greater than 10cm were significantly more common in PHSs than PHSCs (p=0.043) and cystic masses were more detected in PHSs (P=0.041). Both PHSCs and PHSs mainly presented hypovascularity (78.3% vs 81.3%). The ring hyper enhancement on the arterial phase (AP) and wash out were more frequently seen in PHSCs and the iso-hypo enhancement on the AP followed persistent or progressive enhancement was more commonly detected in PHSs (all, p<0.05). Conclusion：PHSC and PHS generally present as mass lesions with hypovascularity. The ring hyper enhancement on the AP and wash out favor the diagnosis of PHSC. The large size greater than 10cm, cystic lesion, iso-hypo persistent or progressive enhancement pattern might suggest the possibility of PHSs.

show abstract

Prognostic Significance of Sarcomatous Change in Patients with Hepatocellular Carcinoma After Surgical Resection

Cited by 21 publications

References 25 publications

Characterization of a new murine cell line of sarcomatoid hepatocellular carcinoma and its application for biomarker/therapy development

Characterization of a new murine cell line of sarcomatoid hepatocellular carcinoma and its application for biomarker/therapy development

Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases

Clinical and imaging characteristics of primary hepatic sarcomatoid carcinoma and sarcoma: a comparative study

Contact Info

Product

Resources

About